Washington University Researchers Uncover Dual Immune Pathways Powering mRNA Cancer Vaccine Efficacy

Washington University researchers find unexpected cDC2 immune pathways that power mRNA cancer vaccines, providing new targets for tumor-killing efficacy.

By: AXL Media

Published: Apr 18, 2026, 4:11 AM EDT

Source: Information for this report was sourced from WashU Medicine

Redefining the Mechanics of mRNA Induced Immunity

The rapid deployment of mRNA technology during the COVID-19 pandemic has set the stage for a new era of oncology, yet the precise cellular mechanics have remained partially obscured. Researchers at Washington University School of Medicine in St. Louis have now challenged the long held assumption that a single specific immune subtype is responsible for the success of these vaccines. In a study published in the journal Nature, scientists demonstrated that mRNA vaccines are far more versatile than previously thought, engaging multiple cellular "teachers" to train the body to hunt and destroy malignant cells. According to Kenneth M. Murphy, a professor of Pathology and Immunology at WashU Medicine, these mechanistic insights are vital for developers aiming to optimize vaccines against specific tumor proteins.

Dendritic Cells Act as Molecular Instructors

At the heart of any mRNA vaccine response is the dendritic cell, a specialized sentinel that processes vaccine instructions to "teach" T cells how to recognize threats. Traditionally, the cDC1 subtype was considered the primary instructor for priming T cells to attack viruses and tumors. However, by utilizing mouse models that lacked these specific cells, the WashU team discovered that the immune system still mounted a formidable defense. This revelation indicates that the body possesses a redundant, highly effective backup system. The research showed that even without the "classical" cDC1 cells, immunized subjects could successfully clear sarcoma tumors, proving that the immune response remained potent and functional.

Unmasking the Role of cDC2 in Tumor Rejection

The study identified the cDC2 cell subtype as the unexpected hero of the mRNA vaccine process. While cDC2 cells are typically not involved in the response to other types of vaccines, they played a pivotal role in stimulating anti-tumor activity in this context. Interestingly, the T cells activated by cDC2 displayed different molecular "fingerprints" compared to those activated by cDC1. This diversity in the immune response suggests that mRNA vaccines do not just create a single type of defense, but rather a multi-pronged attack. According to William E. Gillanders, a surgical oncologist and co-corresponding author, this dual engagement helps explain why mRNA vaccines are uniquely powerful compared...